Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Publication|Articles|March 4, 2025
- April 2025
- Volume 31
- Issue Spec. No. 4
- Pages: SP230
Technology, Partnerships, Data, and Culture Are Keys to Bringing Precision Medicine to Community Oncology
Author(s)Mary Caffrey
Advertisement
Advertisement
In January 2025, former FDA Commissioner Stephen Hahn, MD, and fellow panelists at the JP Morgan investors conference observed that pharma no longer follows a path of establishing a presence in one tumor type before moving to the next—today’s news is all about targets, regardless of where cancer emerges.1
Related to this article
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
AACR urges Congress to protect NIH/NCI funding amid a fight over a contested OMB grantmaking rule.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Advertisement
Advertisement